(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 April 2017 (06.04.2017)

WIPO | PCT

(10) International Publication Number
WO 2017/054754 A1

(51) International Patent Classification:
A61K 31/337 (2006.01) *A61P 35/00* (2006.01)
A61K 9/10 (2006.01)

(21) International Application Number:
PCT/CN2016/100807

(22) International Filing Date:
29 September 2016 (29.09.2016)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/234,868 30 September 2015 (30.09.2015) US

(71) Applicant: **ATHENEX HK INNOVATIVE LIMITED** [CN/CN]; Unit 811-813, IC Development Centre, No. 6 Science Park West Avenue Hong Kong Science Park, Sha Tin, Hong Kong (CN).

(72) Inventors: **CHAN, Denise S.B.**; Room 20, 12F, Fok Cheong Building, 1044 King's Road, Hong Kong (CN). **LEE, Ming Tsung**; Flat 5E, Block C, Lakeside Garden, Sai Kung, New Territories, Hong Kong (CN). **YOON, Weng Li**; Flat C6, South Bay Villa, 4 South Bay Close, Hong Kong (MY). **LAU, Johnson Yiu-Nam**; 9 Seabluff, Newport Beach, CA 92660 (US).

(74) Agent: **CO-HORIZON INTELLECTUAL PROPERTY INC.**; Suite 605, B Block,Yuyang Mansion, No.2, Xiaoguanbeili, Chaoyang District, Beijing 100029 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report (Art. 21(3))*

WO 2017/054754 A1

(54) Title: ORAL TAXANE COMPOSITIONS AND METHODS

Figure 3.2B.



(57) Abstract: A pharmaceutical composition comprises a taxane (e.g., paclitaxel, docetaxel, cabazitaxel, larotaxel, ortataxel, and/or tesetaxel) in a mixture of first and second surfactants. The absorption of the taxane is increased from the pharmaceutical composition is greater than the sum of the absorption of docetaxel from either the first or the second surfactant. The increase in absorption is especially enhanced when the ratio of the first surfactant to the second surfactant in the pharmaceutical composition is between 60:40 and 85:15 by weight, and the total surfactant weight does not exceed 98 % of the total weight. Polysorbate 80, polysorbate 20, and caprylocaproyl polyoxylglycerides serve as suitable first surfactants, and polysorbate 80 or polyethyoxylated castor oil serve as suitable second surfactants. The stability of the pharmaceutical composition may be enhanced by further including a stabilizer (e.g., citric acid and/or ascorbic acid).